May 2002

Despite some success, reproductive cloning in mammals is still a tricky feat. University of Pennsylvania School of Veterinary Medicine researchers, by tracking the gene Oct4 in mice, have shown how its routine failure to reprogram after nuclear transplant commonly prevents the successful development of mammalian embryos (M. Boiani et al., "Oct4 distribution and level in mouse clones: consequences for pluripotency," Genes & Development, 6[10]:1209-19, May 15, 2002). Producing a clone requires tha

For the past century, since learning that radium treatments can decimate tumors, researchers have accelerated their efforts to cure cancer. A savvy, adaptable, and resilient killer, cancer—in its approximately 200 forms—has persisted despite highly toxic regimens, massive public education programs, and armies of researchers working worldwide. "The history of cancer therapy is that the cells are much smarter than the clinicians, and [they] quickly evolve pathways that can bypass the t

In science, things are not always as they seem. So it is for transdifferentiation, the apparent interconvertibility of certain specialized cell types and an underlying theme at a symposium on stem cell biology and applications at the recent annual meeting of the American Association for Cancer Research (AACR) in San Francisco. "For the past three years, people have been saying that hematopoietic [blood-forming] stem cells can become just about any tissue, challenging the paradigm that there are

Are colleges dropping biology laboratories? Some people say yes, while others don't see it. Both sides agree, however, that economic factors could result in the demise of labs in some college biology courses. Paleobotanist Jeffrey Osborn, of the biology department at Truman State University in Kirksville, Mo., is a member of the Council on Undergraduate Research (CUR), a Washington, DC-based consultancy that conducts external reviews for biology departments. The results of these reviews are con

When President George W. Bush signed the Elementary and Secondary Education Act into law early this year, he came close to penning his approval to a provision that many scientists say would have opened the door to antievolution lessons in America's classrooms. Congress passed the new law, which overhauls federal primary and high school education mandates including testing requirements, after a joint conference committee resolved differences between House and Senate versions of the bill. The Sen

A group of speakers selected to embody the past, present, and future of plant science portrayed life's diversity as being in a precarious situation. Half the species on the planet could be wiped out by the end of the century, some say. "We are playing the endgame," said Edward O. Wilson, Pellegrino University professor and curator of entomology at the Museum of Comparative Zoology, Harvard University. The inauguration of a multimillion-dollar plant science center at the New York Botanical Garden

The National Center for Science Education (NCSE), a clearinghouse for information about evolution and the anti-evolutionist initiatives, reported more than one state or local difficulty per week in 1999 and 2000 related to the teaching of evolution. One of the prominent figures in the ongoing evolutionist vs. creationist debate is NCSE executive director Eugenie C. Scott, a physical anthropologist by training. Scott didn't intend to become embroiled in this issue; one of her graduate school prof

Attending the American Association for Cancer Research annual meeting is always a rejuvenating—yet exhausting—experience. First, you get to go to some nice places: New Orleans, San Francisco (twice in three years), even Philadelphia one year. But it's not the places where these meetings are held, but the research you hear about that is simply overwhelming when compressed into a five-day time frame. In this issue, our cancer research focus for this year, we discuss some of the themes

I have lived in this country somewhat longer than in the country of my birth. There are times when I wonder, as is probably true of many expatriates, what I really am. Am I Indian, American, or some bastardized version that is neither? There is not very much in my behavior now that is completely Indian, at least to the casual observer. But at a deeper level, I realize that my reactions to many situations seem to be informed more by my cultural heritage, than by the culture in which I live. I th

Regarding the article "Minorities move ahead by inches,"1 maybe the problem can only be effectively addressed by the redefinition of minorities, cast in terms of culture rather than race: Minority: Person or persons retaining customs and practices at odds with that of society at large. Although this view is distinctly at odds with multiculturism, it is distinctly preferable to the currently widely held view that differences in achievement are due to racial characteristics. Further, it can be eas

Your approach to the ethics of cloning does not represent the views of all of your readers.1 Being a scientist does not preclude a strongly Biblical, pro-life stance. I have spent my 25 professional years in biochemistry and pharmacology labs, both in academia and industry, and I strongly and vocally oppose human cloning of any kind, for any reason. Yes, even a scientist is entitled to the belief that human life (and the human soul) begins at conception, and that cloning is a morally reprehensi

Regarding the article on the 10/90 gap,1 and a Médecins sans Frontières initiative on neglected diseases, the Global Forum for Health Research was established precisely to help correct this 10/90 gap in health research: that is, the misallocation of funding that means that less than 10% of the US $73 billion spent annually by the public and private sectors combined goes to 90% of the world's health problems. For reference, one can download our latest report, "The 10/90 Report on Healt

Data derived from the Science Watch/Hot Papers database and the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. For all that is known about human immunodeficiency virus (HIV), some remarkably fundamental questions remain. One of the most notable, perhaps, is just how HIV manages to infect its primary target, CD4+-T cells, when so few of those cells can be found at the virus' typical entry points: the v

The standard modus operandi for modeling human diseases in the mouse: Find an interesting gene, knock it out, and watch what happens. In theory, the approach makes perfect sense, and scientists have obtained countless subtle insights into the complexities of biology because of it. But mice, of course, are not humans, and many investigators have had to hastily rewrite otherwise elegant theories because of mouse data. One reason? Researchers have taken for granted that telomere length matters. But

From disdain to hype, to mixed results in clinical trials, a sobering reality is setting in for researchers pursuing antiangiogenesis as a treatment for cancer: It is not as straightforward as once hoped. The idea is that choking off a tumor's blood supply will slow or eliminate its growth. But several clinical trials following this line of inquiry have failed or been discontinued. This past February, for example, Sugen, a division of Peapack, NJ-based Pharmacia, announced it was aborting its P

For a team at the University of California, San Diego, nine years of tinkering with arsenic paid off in the development of a new technique that can tag proteins with different colors over time and even zero in to electron microscopic resolution. Roger Tsien, Howard Hughes Medical Institute investigator and professor of pharmacology, chemistry, and biochemistry at UCSD, says the project started with the suggestion from a colleague that one can tag a two-cysteine sequence in a protein with a singl

Madison, Wis.-based Novagen now sells KOD HiFi DNA polymerase (manufactured by Toyobo of Japan), a proofreading enzyme for high-fidelity PCR amplification. KOD HiFi DNA polymerase is a recombinant version of Thermococcus kodakaraensis KOD1 DNA polymerase. According to company literature, the enzyme possesses higher accuracy than any other commercially available DNA polymerase, is five times faster than Pfu DNA polymerase, and twice as fast as Taq DNA polymerase. Novagen also sells KOD Hot Start

After working as a research fellow for nearly seven years at the University of California, San Francisco, Alex Duncan wanted to settle down and raise a family. Rather than stay in the United States, he decided to put down roots in Cambridge, England. The decision wasn't difficult, since both he and his wife were from the United Kingdom, and he had done graduate work at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge. "Cambridge is a vibrant university town with a

Susan Slovin develops vaccines at the Memorial Sloan-Kettering Cancer Center in New York City using tumor- associated antigens for prostrate cancer. She has completed multiple Phase I and Phase II clinical trials, which test safety and dosing. She has designed a Phase III trial for efficacy--the last stage required for approval by the Food and Drug Administration (FDA). Nevertheless, she can't proceed. Scientists are required to use the FDA's Good Manufacturing Practices (GMPs), which makes the

You can never go home again. Sources for my book on alternate careers told me the switch falls in one direction only.1I never dreamed of going back because writing allows me to learn about subjects as different as conservation research and the Y chromosome. Janet Joy, a senior program officer at the National Research Council (NRC) since 1995, says she has no plans to return to the bench either. Before heading to work at the NRC, she was a neuroscientist at the National Institute of Mental Healt

The three top-earning US medical schools, which together garnered nearly $1 billion (US) from the National Institutes of Health in 2001, employ strategies that lesser known institutions can also use, according to administrators. The medical faculties at Johns Hopkins University, the University of Pennsylvania, and the University of California, San Francisco, acquired nearly $982 million in NIH grants, more than 11% of the $8.67 billion awarded to 122 US medical schools in fiscal year 2001. Johns

Click to view our current database of Funding Opportunites in the Life Sciences.